Cymbalta
Trovati 4 articoli
- Cymbalta: a review of safety reports
- Duloxetine ( Cymbalta ) is a serotonin and norepinephrine reuptake inhibitor ( SNRI ) for oral administration initially approved in August 2004 to treat major depressive disorder. Subsequently, FDA approved Duloxetine for the treatment of diabetic peripheral neuropathic pain ( September 2004 ) an... (Leggi Articolo)
- Antidepressants: new warnings about suicidal thinking, behavior in young adults
- The FDA ( Food and Drug Administration ) proposed that makers of all antidepressant medications update the existing black box warning on their products' labeling to include warnings about increased risks of suicidal thinking and behavior, known as suicidality, in young adults ages 18 to 24 during... (Leggi Articolo)
- Duloxetine produces improvements in painful diabetic neuropathy
- A pooled analysis of three studies showed that Duloxetine ( Cymbalta ) significantly improves physical, social and emotional functioning, in addition to overall health, in patients with pain associated with diabetic peripheral neuropathy ( DPNP ), compared with those treated with placebo. In t... (Leggi Articolo)
- Cymbalta reduces anxiety symptoms in elderly with depression
- Duloxetine ( Cymbalta ) significantly reduced anxiety symptoms in elderly patients with depression, compared with those treated with a sugar pill. In the eight-week study of people over age 65 with depression, 60 mg of Duloxetine, taken once daily, significantly reduced psychic anxiety symptom... (Leggi Articolo)
